Group 1 - The Capital Group Companies, Inc. increased its stake in 恒瑞医药 (Hengrui Medicine) by acquiring 1.7282 million shares at an average price of HKD 87.2873 per share, totaling approximately HKD 151 million [1] - Following the acquisition, The Capital Group's total shareholding in 恒瑞医药 rose to 19.7458 million shares, increasing its ownership percentage from 6.98% to 7.65% [1][2]

智通财经APP获悉，香港联交所最新资料显示，9月19日，The Capital Group Companies, Inc.增持恒瑞医 药(01276)172.82万股，每股均价87.2873港元，总金额约为1.51亿港元。增持后最新持股数目为1974.58 万股，最新持股比例为7.65%。 ...

格隆汇9月23日丨恒瑞医药(01276.HK)公告，9月23日耗资8993.6万元回购129.8万股A股。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，于2025年9月23日斥资8993.56万元回购129.8万股A股。 ...

呈交日期： 2025年9月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 20 ...

Core Viewpoint - Heng Rui Medicine's subsidiary Chengdu Shengdi Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of HRS-3095 tablets, aimed at treating chronic spontaneous urticaria (CSU) [1] Group 1: Clinical Trial Approval - The clinical trial application for HRS-3095 tablets was accepted on July 7, 2025, and has met the requirements for drug registration [1] - The drug is designed for patients suffering from chronic spontaneous urticaria (CSU) [1] Group 2: Drug Development - HRS-3095 tablets are a self-developed small molecule compound targeting immune cells, showing promising therapeutic effects for allergic diseases [1] - Preclinical data indicates that HRS-3095 can effectively improve skin allergy symptoms in mice [1] - Currently, there are no approved drugs targeting the same mechanism for CSU in both domestic and international markets [1] Group 3: Research Investment - The total research and development investment for the HRS-3095 project has reached approximately 16.03 million yuan [1]

Core Viewpoint - The company, Heng Rui Medicine, announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the new indication application of its drug, Adebali monoclonal antibody injection [1] Group 1: Product Information - Adebali monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody developed by the company, which can specifically bind to the PD-L1 molecule to block the PD-1/PD-L1 pathway that leads to tumor immune tolerance, thereby reactivating the immune system's anti-tumor activity [1] - Similar products available in the market include Atezolizumab (brand name: Tecentriq), Avelumab (brand name: Bavencio), and Durvalumab (brand name: Imfinzi), which have been approved for sale in the United States, with Atezolizumab and Durvalumab also approved in China [1] Group 2: Market Context - The combined global sales of Atezolizumab, Avelumab, and Durvalumab are approximately $9.648 billion for the year 2024 [1] - The cumulative research and development investment for the Adebali monoclonal antibody injection project has reached approximately 939 million yuan [1]

格隆汇9月23日丨恒瑞医药(01276.HK)发布公告，近日，公司子公司上海盛迪医药有限公司收到国家药 监局下发的《受理通知书》，公司阿得贝利单抗注射液新适应症的药品上市许可申请获国家药监局受 理。 根据披露，本品联合含铂化疗作为新辅助治疗，术后继续以本品作为单药辅助治疗，用于治疗可手术切 除的Ⅱ、ⅢA和ⅢB期且无已知表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)重排的成人非 小细胞肺癌(NSCLC)患者。公司阿得贝利单抗注射液已于2023年2月获批上市，获批的适应症为与卡铂 和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。 ...

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of HRS-3095 tablets, aimed at treating Chronic Spontaneous Urticaria (CSU) [1] Group 1: Clinical Trial Approval - The clinical trial approval notice for HRS-3095 was issued based on compliance with the Drug Administration Law of the People's Republic of China [1] - The application for HRS-3095 was accepted on July 7, 2025, and has met the requirements for drug registration [1] Group 2: Drug Development - HRS-3095 is a small molecule compound developed by the company that targets immune cells and shows promising therapeutic effects for allergic diseases [1] - Preclinical data indicates that HRS-3095 can effectively improve skin allergy symptoms in mice [1] - Currently, there are no approved drugs targeting the same mechanism for CSU in both domestic and international markets [1] Group 3: Research Investment - The total research and development investment for the HRS-3095 project has reached approximately 16.03 million yuan [1]

根据披露，本品联合含铂化疗作为新辅助治疗，术后继续以本品作为单药辅助治疗，用于治疗可手术切 除的Ⅱ、ⅢA和ⅢB期且无已知表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)重排的成人非 小细胞肺癌(NSCLC)患者。公司阿得贝利单抗注射液已于2023年2月获批上市，获批的适应症为与卡铂 和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。 格隆汇9月23日丨恒瑞医药(01276.HK)发布公告，近日，公司子公司上海盛迪医药有限公司收到国家药 监局下发的《受理通知书》，公司阿得贝利单抗注射液新适应症的药品上市许可申请获国家药监局受 理。 ...